Bronchiectasis has been a well-known disease for a long time. Following the introduction of antibiotic treatment in clinical practice for respiratory tract infections, the problem of bronchiectasis appeared to be solved, with some exceptions, e.g. in diseases such as cystic fibrosis. However, bronchiectasis is associated with a number of immunological diseases and occurs as a long-term complication of chronic lung diseases. These types of diseases, mainly chronic obstructive pulmonary disease, have become more and more prevalent, which has again made bronchiectasis a disease of interest. Unfortunately, most of the evidence regarding bronchiectasis is from case series and uncontrolled studies. Bronchiectasis has not been a focus of the pharmaceutical industry and randomised controlled studies have never been performed. Specific guidelines focusing on bronchiectasis are yet to be published.